Cardiolipin-targeting mitochondrial peptide. Phase III Barth syndrome trial (TAZPOWER) failed primary endpoint. Stealth BioTherapeutics dissolved.

📖 Read the full SS-31 (Elamipretide) research overview →

Evidence Tier: Tier ~ — It’s Complicated